gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
TRANSCRIPT
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
1/45
Gastrointestinal
PharmacotherapySarah Nelson, Pharm.D.
March 3, 2009
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
2/45
Objectives
Discuss the process of acid secretion inthe gastrointestinal tract
Differentiate medications used tosuppress gastric acid secretion
Explain the role of gastrointestinal
motility in disease states
Differentiate medications used to accountfor impaired gastrointestinal motility
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
3/45
Gastrointestinal tract
http://www.nationmaster.com/encyclopedia/Gastrointestinal-tract
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
4/45
Disorders of the
Esophagus and Stomach Gastroesophageal Reflux Disease (GERD)
Dyspepsia/Non-erosive reflux disease (NERD)
Esophagitis (erosive)
Peptic ulceration
H. pylori associated peptic ulcers
Ali, T. Miner, P. New Developments in gastroesophageal reflux disease diagnosis and therapy.Curr Opin in Gastroenterology. 2008;24:502-508
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
5/45
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
6/45
Stomach Anatomy
https://reader010.{domain}/reader010/html5/0624/5b2e88bde21ff/5b2e88c094d33.jpg
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
7/45
Defense Mechanisms
Lower esophageal sphincter
Secretion of gastric mucus
Stimulated by prostaglandin E2and I2
Secretion of bicarbonate ions
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
8/45
GERD
Definition: when the reflux of stomachcontents causes troublesome symptomsor complications
Diagnosis:
Presence of symptoms
Demonstration of reflux
Identification of existing damage fromreflux
Ali, T. Miner, P. New Developments in gastroesophageal reflux disease diagnosis and therapy.Curr Opin in Gastroenterology. 2008;24:502-508
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
9/45
Epidemiology
44% of adults in the US experienceheartburn 1 time/month
Up to 15-18% of adults in the USexperience heartburn weekly
Heartburn or substernal burning is the
most commonly recognizedmanifestation of GERD
Shaheen, N., Ransohoff, D.F. Gastroesophageal Reflux, Barrett Esophagus, and Esophageal Cancer: Scientific Review. JAMA. 2002;287(15):1972-1981
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
10/45
Risk Factors for GERD
Obesity
Food (spicy, chocolate, peppermint)
Age
Smoking
CaffeineAlcohol
Pregnancy
Dipiro, Joseph et al. Pharmacotherapy: A Pathophysiologic Approach. 6thEdition. USA; McGraw-Hill Company, 2005.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
11/45
Stages of GERDStage Description Medical
Management
I (NERD) sporadic
2-3 episodes/wk
Lifestyle modification
Antacids/H2 RA asneeded
II Frequent symptoms
+/- esophagitis
PPI vs. H2RA
III Chronic, unrelenting
Immediate relapseoff therapy
Esophagealcomplications
PPI once or twice
daily
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
12/45
Treatment of GERD
Decrease acidity of stomach contents
Antacids
H2 receptor antagonists
Proton pump inhibitors
Protect gastric mucosa sucralfate
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
13/45
Antacids
Chemically neutralize stomach acid
Base (OH)3or CO3 + Al, Ca, or Mg
CaCO3= calcium carbonate (Tums)
Al (OH)3+ Mg (OH)2= Maalox
Some contain simethicone (a surfactant)Al (OH)3+ Mg (OH)2+ simethicone = Mylanta
Site GI chapter
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
14/45
Antacids
Mechanism of Action:
Antacid + HCl salt + water
Examples
Al(OH)3+ 3 HCl AlCl3+ 3H2O
CaCO3+ 2 HCl CaCl2+ 2H20 + CO2
Site GI chapter
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
15/45
Antacids
Side Effects
Constipation (Al containing products)
Diarrhea (Mg containing products) Electrolyte imbalances
Decreases absorption of other drugs
Place in Therapy
Minor, infrequent dyspepsia
With other acid suppressants on an as neededbasis
Calcium supplementation
Site GI chapter
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
16/45
H2-Receptor Antagonists
Block histamine from binding to H2receptors on parietal cell
Decrease rate of activation byhistamine decreased acid secretion
Blocks basal and bolus acid secretion Basal: continuous acid secretion Bolus: secretion in response to stimuli
(food, etc)
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
17/45
H2-Receptor Antagonists
Cimetidine (Tagamet) Not used often due to drug interactions
Ranitidine (Zantac) 150-300mg by mouth twice daily
Famotidine (Pepcid)
20-40mg by mouth twice daily Nizatidine (Axid)
150-300mg by mouth twice daily
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
18/45
H2-Receptor Antagonists
Side Effects
Well tolerated
Many drug interactions, esp. with HIVmedication
Tolerance can develop with long term use
Place in Therapy
As needed for minor dyspepsia
Daily to control frequent symptoms
Low dose for symptoms w/o esophagitis
High dose for symptoms w/ esophagitis
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
19/45
Proton Pump Inhibitors
Most potent inhibitors of acid secretion
Decrease daily acid secretion 80-95%
Require activation by acid in stomach Irreversibly binds and inactivates the
H+/K+-ATPase
H+/K+-ATPase is the pump molecule thatsecretes acid from the parietal cell intothe lumen of the stomach
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
20/45
Proton Pump Inhibitors
Drug Healing PreventionOmeprazole (Prilosec) 20-40mg daily 20mg daily
Esomeprazole (Nexium) 20-40mg daily 20mg daily
Lansoprazole (Prevacid) 15-30mg daily 15 mg daily
Pantoprazole (Protonix) 40mg daily 20-40mg daily
Rabeprazole (Aciphex) 20mg daily 20mg daily
Site GI chapter
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
21/45
Proton Pump Inhibitors
Side Effects Well tolerated
Takes multiple doses to get full effect Place in Therapy
Symptomatic GERD with esophagitis
Promote healing of gastric ulcers Hypersecretory conditions
Prevent NSAID-associated gastric ulcers
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
22/45
Miscellaneous
Other medications used for GERD Prostaglandin analogues (i.e. misoprostol)
Bind a EP3receptor on parietal cells, decreasingcAMP (energy) available for H+/K+-ATPase
Sucralfate Sucrose + Al(OH)3which forms a viscous layer on
the gastric mucosa Prevents acid from contacting mucosa
Metoclopramide Stimulates gastric motility increased
clearance of stomach acidSite GI chapter
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
23/45
Complications of GERD
Ulceration (w/ or w/o H. pylori)
Asthma exacerbations
Esophageal strictures
Adenocarcinoma
Barrett Esophagus
Shaheen, N., Ransohoff, D.F. Gastroesophageal Reflux, Barret Esophagus, and Esophageal Cancer: Scientific Revies. JAMA. 2002;287(15):1972-1981Dougherty, R., Fahy, J. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype.Clinical and Experimental Allergy.2009;39(2):193-202
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
24/45
H. Pylori Infection
Gram-negative rod
Not always associated with an activeulcer
Associated with gastritis, leads to: Gastric/duodenal ulcers
Gastric adenocarcinoma
Gastric B-cell lymphoma
Eradication is standard of care topromote healing of ulcer and to prevent
recurrenceBrunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
25/45
H. Pylori Infection
3 Drug Combination Proton pump inhibitor (high dose)
2 antibiotics (clarithromycin + amoxicillin ORmetronidazole
4 Drug Combination Proton pump inhibitor (high dose)
2 antibiotics (metronidazole + tetracycline ORamoxicillin OR clarithromycin)
Bismuth subsalicylate
All regimens 14 days in duration Patient compliance is difficult with intense regimens
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
26/45
Acid-rebound Phenomenon
Chronic suppression of acid secretionleads to hypergastrinemia
Gastrin stimulates ECL cells to releasehistamine increased acid secretionfrom activation of histamine receptor onparietal cell
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
27/45
Disorders of the Lower GI
Tract Constipation
Diarrhea
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
28/45
Gastrointestinal Motility
The GI tract is in a continuous contractile,absorptive, & secretory state
Muscle, CNS, ENS (enteric nerve system),and humoral pathways control GImovement
4 phases to movement in the GI tract Peristalsis is most important, moves contents
through GI tract
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
29/45
GI Motility
https://reader010.{domain}/reader010/html5/0624/5b2e88bde21ff/5b2e88cc0a0cc.jpg
increased transit time
- Increased waterabsorption constipation
decreased transit time
-Decreased water andnutrient absorption diarrhea
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
30/45
Constipation
Affects up to 27% of Americans
Accounts for 2.5 mil. physician visits/year
$400 million spent on OTCs annually
Definition
Unsatisfactory defecation that results ininfrequent stool, difficult stool passage, orboth
Cash, B. et al. Update on the Management of Adults with Chronic Idiopathic Constipation.The Journal of Family Practice. 2007;56(6):S13-20
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
31/45
Constipation
http://www.helpfulhealthtips.com/Images/C/constipation1.jpg
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
32/45
Causes of Constipation
GI disorders Irritable bowel syndrome, hernia, anal
fissures Metabolic disorders
Diabetes with neuropathy, hypothyriodism
Pregnancy
Psychogenic disorders
MedicationsAnalgesics, antacids, iron preparations
Dipiro, Joseph et al. Pharmacotherapy: A Pathophysiologic Approach. 6thEdition. USA; McGraw-Hill Company, 2005.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
33/45
Treatment of Constipation
Lifestyle modifications Fiber-rich dietAdequate fluid intake
Appropriate bowel habits and training Exercise
Medications Bulk-forming laxatives
Stimulant laxatives Hyperosmotic laxatives Stool softeners
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
34/45
Bulk-Forming Laxatives
3 kinds
Psyllium (Metamucil)
Methylcelluose (Citrucel) Calcium polycarbophil (Fibercon)
Increases colonic mass which triggers
peristalsis Increases water content of stool via
hydrophilic forcesBrunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
35/45
Stimulant Laxatives
Induce low-grade inflammation in the small and largeintestine Promotes accumulation of water and stimulates
motility Provides soft or semifluidstool in 6-12 hours Bisacodyl (Dulcolax)
5-15 mg by mouth daily; 10mg rectally daily (rectaladministration effective within 1 hour)
Castor Oil Senna (Senokot)
8.6mg sennosides 1-2 times per day (1-2 tabletsonce or twice daily)
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
Dipiro, Joseph et al. Pharmacotherapy: A Pathophysiologic Approach. 6thEdition. USA; McGraw-Hill Company, 2005.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
36/45
Hyperosmotic Laxatives
Osmotically mediated water retention (viacations-Al, Mg, etc) which stimulatesperistalsis
Provides wateryfecal evacuation in 1-6 hours
Magnesium hydroxide (Milk of Mag) 5-15mL by mouth four times daily
Polyethylene glycol (Miralax
) Dose used depends on level of evacuation
Sodium phosphate (Fleets Phosphosoda)
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
Dipiro, Joseph et al. Pharmacotherapy: A Pathophysiologic Approach. 6thEdition. USA; McGraw-Hill Company, 2005.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
37/45
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
38/45
Diarrhea
Prevalence of diarrhea varies in developed vs.non-developed countries
1.3 billion episodes/yr in developing countries4 million deaths
Can be associated with an infectious cause
Shigella, Salmonella, E. Coli among most common
Most diarrhea is self-limiting
Defined as an increase in stool frequency orwater content
Dipiro, Joseph et al. Pharmacotherapy: A Pathophysiologic Approach. 6thEdition. USA; McGraw-Hill Company, 2005.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
39/45
Diarrhea
http://www.ghi.com/WebMD/topics/diarrhea.jpg
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
40/45
Opioid Derivatives
Bind the -receptor on enteric nerves,epithelium, and muscle
Decrease GI motility Increase absorption of water from the bowel
Diphenoxylate (Lomotil)
5mg by mouth 4 times daily (max 20mg/day)
Loperamide (Immodium)
4mg by mouth first, then 2mg by mouth aftereach loose stool (max 16mg/day)
Site GI chapter
Dipiro, Joseph et al. Pharmacotherapy: A Pathophysiologic Approach. 6thEdition. USA; McGraw-Hill Company, 2005.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
41/45
Adsorbents
Non-selectively absorbs intestinal fluid
Regulates stool texture and viscosity
Bind bacterial toxins and bile saltsAttapulgite (Kaopectate)
30-120mL after each loose stool
Can bind other medications, mustspace out from others by 2 to 3 hours
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
42/45
Bismuth Salicylate
Anti-secretory, anti-inflammatory,antimicrobial effects
Used for the prevention and treatmentof travelers diarrhea
PeptoBismol
30mL (2 tabs) every hour as needed (upto 8 times/day)
Excessive use can lead to salicylatepoisioning
Brunton, Laurence. Goodman & Gillmans The Pharmacological Basis of Therapeutics.11thEdition. USA; McGraw-Hill Company, 2006.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
43/45
Probiotics
Replaces normal colonic microflora
Restores intestinal function and suppresses thegrowth of pathogenic bacteria
Lactobacillus acidophilus (Lactinex)
2 tabs or 1 packet of granules 3-4 times daily
Dairy Products
200-400 grams of lactose
Special lactobacillus containing yogurts
Dipiro, Joseph et al. Pharmacotherapy: A Pathophysiologic Approach. 6thEdition. USA; McGraw-Hill Company, 2005.
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
44/45
Conclusion
Approximately 1/3 of your patients willbe taking a medication for GERD
Approximately of your patients willbe taking a medication for constipation
GERD, constipation, and diarrheaaffect a patients quality of life
-
8/13/2019 gastrointestinalpharmacotherapypptfinal-12639285176985-phpapp01
45/45
Questions?